Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group

Reuters

Feb 06

Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group

Tasly Pharmaceutical Group Co., Ltd., an affiliate of China Resources Pharmaceutical Group Ltd., released its unaudited preliminary financial results for the year ended 31 December 2025. China Resources Pharmaceutical Group Ltd. holds approximately a 28% equity interest in Tasly Pharmaceutical through its non-wholly-owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. In 2025, Tasly Pharmaceutical became a member of the CR Sanjiu group, completing a "100-day integration" and accelerating resource integration. For the year, Tasly Pharmaceutical reported total operating revenue of RMB 8,236.48 million, a 3.08% decrease year-on-year, and net profit attributable to shareholders of RMB 1,105.40 million, an increase of 15.68%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018348), on February 06, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2609935015"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2609935015\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2609935015?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-06 20:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2609935015","market":"us","top_or_hot":-1,"title":"Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tasly Pharmaceutical Group Co., Ltd., an affiliate of China Resources Pharmaceutical Group Ltd., released its unaudited preliminary financial results for the year ended 31 December 2025. China Resources Pharmaceutical Group Ltd. holds approximately a 28% equity interest in Tasly Pharmaceutical through its non-wholly-owned subsidiary, China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd. In 2025, Tasly Pharmaceutical became a member of the CR Sanjiu group, completing a \"100-day integration\" and accelerating resource integration. For the year, Tasly Pharmaceutical reported total operating revenue of RMB 8,236.48 million, a 3.08% decrease year-on-year, and net profit attributable to shareholders of RMB 1,105.40 million, an increase of 15.68%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018348), on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-02-06 20:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tasly Pharmaceutical Group Co., Ltd., an affiliate of China Resources Pharmaceutical Group Ltd., released its unaudited preliminary financial results for the year ended 31 December 2025. China Resources Pharmaceutical Group Ltd. holds approximately a 28% equity interest in Tasly Pharmaceutical through its non-wholly-owned subsidiary, China Resources Sanjiu Medical &amp; Pharmaceutical Co., Ltd. In 2025, Tasly Pharmaceutical became a member of the CR Sanjiu group, completing a \"100-day integration\" and accelerating resource integration. For the year, Tasly Pharmaceutical reported total operating revenue of RMB 8,236.48 million, a 3.08% decrease year-on-year, and net profit attributable to shareholders of RMB 1,105.40 million, an increase of 15.68%.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018348), on February 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0185","symbol_name":"二线龙头","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260206:nNDL5Fc3Bw:1","article_id":"2609935015","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2609935015","pubTimestamp":1770381292,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tasly Pharmaceutical Group Co., Ltd., an affiliate of China Resources Pharmaceutical Group Ltd., released its unaudited preliminary financial results for the year ended 31 December 2025. China Resources Pharmaceutical Group Ltd. holds approximately a 28% equity interest in Tasly Pharmaceutical through its non-wholly-owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. In 2025, Tasly Pharmaceutical became a member of the CR Sanjiu group, completing a \"100-day integration\" and accelerating resource integration. For the year, Tasly Pharmaceutical reported total operating revenue of RMB 8,236.48 million, a 3.08% decrease year-on-year, and net profit attributable to shareholders of RMB 1,105.40 million, an increase of 15.68%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600535":"天士力","BK0185":"二线龙头","03320":"华润医药","BK0239":"医药制造","BK0183":"MSCI概念","000999":"华润三九","BK1191":"制药","BK0188":"融资融券","BK1570":"华润系","BK0012":"证金概念","BK0175":"白马股","BK0060":"抗癌","BK0196":"行业龙头","BK0010":"央企","BK0028":"国家队"},"translate_title":"华润医药集团旗下天士力药业子公司公布2025年初步业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600535":0.9,"000999":0.9,"03320":0.9},"content_text":"Tasly Pharmaceutical Affiliate Posts Preliminary 2025 Results Under China Resources Pharmaceutical Group\n    \n\n        Tasly Pharmaceutical Group Co., Ltd., an affiliate of China Resources Pharmaceutical Group Ltd., released its unaudited preliminary financial results for the year ended 31 December 2025. China Resources Pharmaceutical Group Ltd. holds approximately a 28% equity interest in Tasly Pharmaceutical through its non-wholly-owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. In 2025, Tasly Pharmaceutical became a member of the CR Sanjiu group, completing a \"100-day integration\" and accelerating resource integration. For the year, Tasly Pharmaceutical reported total operating revenue of RMB 8,236.48 million, a 3.08% decrease year-on-year, and net profit attributable to shareholders of RMB 1,105.40 million, an increase of 15.68%.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Resources Pharmaceutical Group Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260206-12018348), on February 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}